The BCR-ABL Control Panels are intended for use as reference material to monitor the performance of the in vitro quantitative detection of BCR-ABL1 translocation mRNA e14a2 (p210), e13a2 (p210), e1a2 (p190) transcripts and the ABL1 endogenous control mRNA transcript. The products consist of purified RNA transcripts meticulously blended to give from 10%IS (MR1.0) down to 0.001%IS (MR5.0). The IS vales for the e14a2 (p210) are calibrated to the WHO International Standard (NIBSC code: 09/138). The controls work well on the Xpert® BCR-ABL Ultra assay on Cepheid GeneXpert® Instrument Systems.
If you need customized controls, please feel free to contact us at info@anchormolecular.com or call +1 925-400-9986—we’re happy to assist.
The Extraction Controls are either ctDNA spiked in plasma at a fixed allele frequency (Panel 1) or wild-type cfDNA spiked in plasma at a fixed concentration (Panel 2). They are used as controls to help monitor cfDNA extraction efficiency from real human plasma, determine how low the absolute number of copies can be reliably extracted, and standardize the QC workflow for the cfDNA extraction process.
cfDNA fragments (~170bp) are mixed with full length genomic DNA background in real human plasma. The control is used for evaluating size specificity of cfDNA extraction by the extraction kit or method. A good cfDNA extraction method should preferentially extract the 170bp cfDNA only while excluding the full length chromosomal DNA.
Microsatellite instability (MSI) is a molecular biomarker resulting from defects in the DNA mismatch repair (MMR) system, leading to alterations in microsatellite repeat lengths throughout the genome. MSI testing is widely used in colorectal, gastric, endometrial, and other cancers to support cancer characterization and identify patients who may benefit from targeted treatment approaches.
The MSI Controls contain formalin-fixed, paraffin-embedded (FFPE) curls with embedded cellular DNA exhibiting microsatellite instability. The MSI-H control contains instability at clinically relevant microsatellite loci commonly used for MSI assessment. These controls are designed for MSI assay development, validation, workflow monitoring, and routine quality control applications. The MSI-H control is formulated to contain approximately 16.7% MSI-H cellular content, providing a challenging reference material for assay verification, sensitivity assessment, and routine quality control applications.
Anchor Molecular offers a comprehensive collection of over 50 commonly observed RNA fusions, organized into eight multiplexed panels optimized for PCR- and NGS-based detection workflows. Each panel contains fusion RNAs at equal copy numbers, ensuring consistent and reliable performance across targets. Designed as a single, consistent, and flexible control source, Anchor Molecular’s Multiplexed RNA Fusion Panels help molecular labs, kit developers, and oncology researchers save time, reduce costs, and streamline regulatory validation.
Panels 6 and 7 include fusions frequently associated with hematologic cancers.
Panels 1, 2, 3, 4, 5, and 8 feature five to seven multiplexed fusions commonly found in solid tumors.
For broader applications, the Multiplexed RNA Fusion Mix v2 combines all solid tumor fusions into a single, convenient panel.
All panels are available as purified RNA in buffer or in FFPE format, supporting a wide range of research and diagnostic applications. For detailed information of each RNA fusion in each panel, here is the link.
We also offer individual RNA fusion controls and BCR-ABL1 panels, available under separate product categories.
To inquire about custom RNA fusions in human plasma or other formats, please contact us at info@anchormolecular.com or +1 925-400-9986 for quote.
AM Normal cfDNA-1: gDNA is nucleosomally fragmented from a popular normal male cell line
AM Normal cfDNA-2: gDNA is nucleosomally fragmented from normal female cell line
AM Normal cfDNA-3: gDNA is nucleosomally fragmented from pooled normal peripheral blood mononuclear cells (PBMC) from fresh blood
Please view "Description" tab below for product detail and price.
AM Normal cfDNA-1: DNA is extracted and fragmented from a popular normal male cell line
AM Normal cfDNA-2: DNA is extracted and fragmented from normal female cell line
AM Normal cfDNA-3: DNA is extracted and fragmented from pooled normal peripheral blood mononuclear cells (PBMC) from fresh blood
The PIK3CA-AKT1 Mutation Controls contain formalin-fixed, paraffin-embedded (FFPE) slices with embedded cellular DNA carrying 23 PIK3CA mutations and AKT1 E17K. The mutations are grouped into seven panels, enabling flexible and targeted assay verification across multiple testing needs. These controls are intended for use in molecular assays, such as the Idylla™ PIK3CA-AKT1 Mutation Assay. The multiplexed PIK3CA–AKT1 Mutation Control (covering 7 panels) can be used for initial feasibility, assay optimization, or routine QC.
If you need customized controls for NGS testing, please feel free to contact us at info@anchormolecular.com or call +1 925-400-9986—we’re happy to assist.
The POLE-POLD1 Mutation Controls contain formalin-fixed, paraffin-embedded (FFPE) slices with embedded cellular DNA carrying POLE mutations on Exon 9 (P286R), Exon 11 (F367S), Exon 13 (V411L, c.1231 G>C ) and Exon 14 (S459F ) and a POLD1 mutation on Exon 12 (S478N). All variants are present at an approximate 5% allele frequency. These controls are intended for use in molecular assays, including the Idylla™ POLE-POLD1 Mutation Assay and NGS-based testing platforms such as oncoReveal® Nexus 21 Gene Panel from Pillar Biosciences. The multiplexed POLE-POLD1 Control (covering 5 mutations) can be used for initial feasibility, assay optimization, or routine QC.
If you need customized controls for NGS testing, please feel free to contact us at info@anchormolecular.com or call +1 925-400-9986—we’re happy to assist.
